The rating downgrade is based on a number of factors, including a decline in EMHS’ operating cash flow margins.
The outlook is negative, reflecting the challenges EMHS will likely face in improving its margins.
Moody’s has also assigned a “Baa3” rating to EMHS’ proposed $162 million of series 2016A bonds and $80 million of series 2016B bonds.
More articles on healthcare finance:
SD hospital abruptly closes surgical, OB departments after clinician’s death
20 most costly inpatient conditions
5 health systems with strong finances
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
